News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 724
- Sources here
- 24
- Companies here
- 15
Active search
724 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Codexis, Inc. Q2 2026 Earnings Call Summary
Codexis, Inc. reported a return to growth in its pharma biocatalysis business, driven by new product approvals and a significant label expansion. The company is strategically focusing on industrializing its ECOsynthesis platform to address projected siRNA demand, backed by recent equity financing and improved …
Standex International Corporati (SXI) Stock forecasts
Argus has lowered its target price for Standex International Corp (SXI) to $325.00, according to a report published on July 29, 2026. Standex International is an industrial manufacturer serving commercial and industrial markets. The current price of SXI is $333.02.
Codexis narrows Q2 loss, raises $25M to fund GMP expansion
Codexis Inc. (NASDAQ: CDXS) significantly narrowed its Q2 2026 net loss to $12.0 million and beat EPS estimates, though revenue slightly declined. The company also secured $25 million in equity financing, extending its cash runway until 2028 and enabling the expansion of its ECO …
DexCom’s 37.5% quarter puts CGM maker within 3.5% of its high as volume stays moderate
DexCom closed at $84.75 after a ninth week in an active Trend Signal, but participation is only 1.1x baseline and the signal mix is balanced rather than emphatic.
Codexis outlines $72M-$76M 2026 revenue as it plans ~$25M GMP facility build-out
Earnings Call Insights: Codexis (CDXS) Q2 2026 MANAGEMENT VIEW * CEO Alison Moore said Codexis delivered “solid financial results for the second quarter of 2026 with revenue of $14.9 million” and highlighted that a financing “resulted in a capital raise of $25 million of …
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress
Celldex Therapeutics (CLDX) reported wider Q2 and first-half losses totaling US$73.5 million and US$152.19 million, respectively, yet its stock rose by 10.7%. This increase is attributed to positive Phase 1 data for bispecific antibody CDX-622 and continued Phase 3 progress for barzolvolimab, despite minimal …
Memphis airport renamed after late FedEx founder Frederick W. Smith
Memphis International Airport has been officially renamed Frederick W. Smith International Airport in honor of the late FedEx founder. The dedication ceremony took place on what would have been Smith's 82nd birthday, recognizing his profound impact on Memphis as a global logistics hub. The …
Earnings call transcript: Codexis beats Q2 2026 estimates as shares rise after hours
Codexis, Inc. reported a return to growth in its pharma biocatalysis business, driven by new product approvals and a significant label expansion. The company is strategically focusing on industrializing its ECOsynthesis platform to address projected siRNA demand, backed by recent equity financing and improved …
IDEX Corp. stock outperforms competitors on strong trading day
IDEX Corp. (IEX) saw its stock rally 1.73% to $237.31 on a tough trading day for the broader market, outperforming the S&P 500 and Dow Jones Industrial Average, which both fell. The company's stock closed 2.66% below its 52-week high reached on July 29th. …
Why Is Standex (NYSE:SXI) Gaining as NYSE Composite Sales Grow 8.1%?
The article discusses Standex International (NYSE:SXI), an industrial company operating in various technological and manufacturing sectors globally. It highlights that Standex is gaining as the NYSE Composite sales grow by 8.1% but provides limited public content, requiring users to log in or register to …
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock fell 1.53% on Tuesday, closing at $586.64, despite a general downturn in the stock market. The S&P 500 Index and Dow Jones Industrial Average also saw declines of 0.32% and 0.34%, respectively. The company's stock is now 23.81% below …
Memphis airport officially renamed Frederick W. Smith International Airport
The Memphis airport has been officially renamed Frederick W. Smith International Airport in honor of FedEx founder Fred Smith. The airport authority unanimously voted for the name change following Smith's passing last June. The airport's code, MEM, will remain the same.
Codexis Reports Second Quarter 2026 Financial Results
Codexis, Inc. reported its second-quarter 2026 financial results, with total revenues of $14.9 million. The company reiterated its full-year 2026 financial guidance, projecting revenues between $72 million and $76 million. Key highlights include advancements in RNA therapeutic manufacturing, a successful equity capital raise of …
Memphis International Airport officially renamed after FedEx founder
Memphis International Airport has been officially renamed Frederick W. Smith International Airport, honoring the late FedEx founder. The renaming ceremony took place on Tuesday, August 11th, with hundreds in attendance to witness the historic event. Richard Smith, FedEx Corp. senior executive and son of …
IDEXX (IDXX) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, …
Sharemaestro market context Price above Trend Line 52 weeks -13.7% · Next-week setup negative 32.7%IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
IDEXX Laboratories, Inc. has launched the Catalyst™ proBNP Test, a new dual-species, in-clinic test for NT-proBNP, expanding its cardiac diagnostic capabilities. This test provides rapid, accurate quantitative cardiac assessment for cats and dogs directly at the point of care, addressing a significant need in …
Sharemaestro market context Price above Trend Line 52 weeks -13.7% · Next-week setup negative 32.7%IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment
IDEXX Laboratories has introduced the Catalyst proBNP Test, designed for in-clinic assessment of cardiac disease in animals. This launch is expected to enhance veterinary diagnostics by providing rapid and accurate results. The company, a leader in veterinary diagnostics, continues to innovate in the animal …
IDEXX Test Brings Heart-Disease Results for Cats and Dogs in Minutes
IDEXX Laboratories has launched the Catalyst™ proBNP Test, a new in-clinic diagnostic tool for heart disease in cats and dogs. This dual-species test provides quantitative NT-proBNP results in minutes, allowing veterinarians to assess cardiac health and make informed treatment decisions faster. The test expands …